Seeking Alpha1d
Bristol-Myers Squibb: Buy This Bargain Before It's Gone
Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...
Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
pharmaphorum3h
J&J plots filings after psoriasis drug clears phase 3 test
Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...
Bristol Myers Faces Renewed, $6.7 Billion Lawsuit Over Delayed Cancer Drug
The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by ...
Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)
In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a ...
What's Next For BMY Stock After An Upbeat Q3?
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
Fintel on MSN3d
Wolfe Research Initiates Coverage of Bristol-Myers Squibb Company - Preferred Security (BMYMP) with Peer Perform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb Company - Preferred ...
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...